SEC Form 4 · accession 0001387131-18-006074
TherapeuticsMD, Inc. · TXMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel A Cartwright
Officer — CFO
Period of report
Nov 7, 2018
Accepted (ET)
Nov 13, 2018 · 7:35 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000025743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 7, 2018 | M | 40,000 | $0.38 | A | 40,000 | D | |
| Common StockF2 | Nov 7, 2018 | S | 40,000 | $4.85 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $0.38 | Nov 7, 2018 | M | 40,000 | D | Oct 21, 2012 | Oct 21, 2021 | Common Stock | 40,000 | 220,000 | D |
Explanation of responses
- F1The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.68 to $4.955, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.